Karen Briscoe

2.2k total citations
21 papers, 557 citations indexed

About

Karen Briscoe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Karen Briscoe has authored 21 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Pharmacology. Recurrent topics in Karen Briscoe's work include Cancer Immunotherapy and Biomarkers (6 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Cannabis and Cannabinoid Research (3 papers). Karen Briscoe is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Cannabis and Cannabinoid Research (3 papers). Karen Briscoe collaborates with scholars based in Australia, United Kingdom and United States. Karen Briscoe's co-authors include Pablo Fernández‐Peñas, Martin R. Stockler, Anna K. Nowak, Hui‐Ming Lin, Girish Mallesara, Brett Hughes, Lisa G. Horvath, Gavin Marx, Kate Mahon and Howard Gurney and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Karen Briscoe

20 papers receiving 550 citations

Peers

Countries citing papers authored by Karen Briscoe

Since Specialization

Citations

This map shows the geographic impact of Karen Briscoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Briscoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Briscoe more than expected).

Fields of papers citing papers by Karen Briscoe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Briscoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Briscoe. The network helps show where Karen Briscoe may publish in the future.

Co-authorship network of co-authors of Karen Briscoe

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Briscoe. A scholar is included among the top collaborators of Karen Briscoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Briscoe. Karen Briscoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer	The Prostate	Kate Mahon, Hui‐Ming Lin et al.	5
2	Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study	The Medical Journal of Australia	Annette M. Lim, Mathias Bressel et al.	8
3	586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial	Annals of Oncology	Daphne Day, Val Gebski et al.	1
4	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial	British Journal of Cancer	Michael Friedländer, Linda Mileshkin et al.	9
5	Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.	Journal of Clinical Oncology	Adrienne Kirby, Martin R. Stockler et al.	5
6	Immunotherapy-related gastritis: Two case reports and literature review	Clinical Medicine Insights Oncology	Rachel Woodford, Karen Briscoe et al.	9
7	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in	The Lancet Oncology	Anna K. Nowak, W. Joost Lesterhuis et al.	115
8	Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration resistant prostate cancer		Hui‐Ming Lin, Daniel Cain et al.	0
9	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)	BMJ Open	Annette Tognela, Paul Haber et al.	19
10	Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)	Annals of Oncology	Annette Tognela, Paul Haber et al.	4
11	OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result	Journal of Thoracic Oncology	Anna K. Nowak, Peey‐Sei Kok et al.	25
12	A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer	International Journal of Cancer	Hui‐Ming Lin, Kate Mahon et al.	63
13	Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer	British Journal of Cancer	Hui‐Ming Lin, Kate Mahon et al.	48
14	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression	JAMA Oncology	Georgina V. Long, Jeffrey S. Weber et al.	126
15	Toxic Epidermal Necrolysis–like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma	Journal of Immunotherapy	Karen Briscoe, Pablo Fernández‐Peñas et al.	79
16	Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTG NITRO trial of 1st line chemotherapy for advanced non–small-cell lung cancer.	Journal of Clinical Oncology	Annette Tognela, David Espinoza et al.	2
17	Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).	Journal of Clinical Oncology	Kate Mahon, Hui‐Ming Lin et al.	1
18	EviQ cancer treatments online (www.eviQ.org.au): A widely used Australian resource.	Journal of Clinical Oncology	Robyn L. Ward, Aisling Kelly et al.	3
19	Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?	European Journal of Cancer	Prunella Blinman, V. Duric et al.	33
20	Total care. Recent advances in the treatment of children with cancer.	Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)	D.J.D. Rosen, Robert C. Trueworthy et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact